EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (NasdaqGM:ADLR) today announced that it has been awarded a second round of funding by the Michael J. Fox Foundation for Parkinson's Research (MJFF) to support the development of selective centrally-acting mu opioid receptor antagonists (CAMORs) for the treatment of l-DOPA-induced dyskinesia (LID) associated with Parkinson's disease. The $363,400 award will be paid over a period of 18 months.
